Luminex Co. (LMNX) Expected to Post Quarterly Sales of $83.12 Million

Equities research analysts expect that Luminex Co. (NASDAQ:LMNX) will post sales of $83.12 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Luminex’s earnings, with the highest sales estimate coming in at $83.40 million and the lowest estimate coming in at $82.80 million. Luminex posted sales of $82.66 million during the same quarter last year, which would indicate a positive year over year growth rate of 0.6%. The firm is scheduled to issue its next quarterly earnings report on Monday, May 6th.

On average, analysts expect that Luminex will report full-year sales of $341.63 million for the current financial year, with estimates ranging from $340.83 million to $342.56 million. For the next financial year, analysts forecast that the business will post sales of $375.97 million, with estimates ranging from $368.30 million to $388.87 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Luminex.

Luminex (NASDAQ:LMNX) last posted its quarterly earnings data on Monday, February 4th. The medical instruments supplier reported $0.04 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.08). Luminex had a return on equity of 4.61% and a net margin of 5.81%. The business had revenue of $81.10 million for the quarter, compared to the consensus estimate of $80.76 million. During the same period in the previous year, the firm earned $0.20 EPS. The company’s revenue was up 3.7% on a year-over-year basis.

Several research firms recently commented on LMNX. ValuEngine lowered shares of Luminex from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 21st. TheStreet lowered shares of Luminex from a “b-” rating to a “c+” rating in a research note on Friday, December 14th. BidaskClub lowered shares of Luminex from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. Finally, Zacks Investment Research raised shares of Luminex from a “sell” rating to a “hold” rating in a research note on Tuesday, March 19th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $28.40.

NASDAQ:LMNX traded down $0.09 during mid-day trading on Monday, hitting $23.01. 353,806 shares of the company’s stock were exchanged, compared to its average volume of 391,042. Luminex has a one year low of $19.20 and a one year high of $35.37. The firm has a market capitalization of $1.03 billion, a P/E ratio of 47.94, a PEG ratio of 6.02 and a beta of 0.79.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 11th. Investors of record on Thursday, March 21st will be paid a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 1.04%. The ex-dividend date is Wednesday, March 20th. Luminex’s payout ratio is currently 50.00%.

Several hedge funds and other institutional investors have recently modified their holdings of LMNX. US Bancorp DE lifted its stake in shares of Luminex by 4,090.5% in the third quarter. US Bancorp DE now owns 11,063 shares of the medical instruments supplier’s stock worth $335,000 after buying an additional 10,799 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Luminex by 11.9% in the third quarter. JPMorgan Chase & Co. now owns 154,554 shares of the medical instruments supplier’s stock worth $4,685,000 after buying an additional 16,401 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Luminex by 1.5% in the third quarter. Bank of New York Mellon Corp now owns 682,988 shares of the medical instruments supplier’s stock worth $20,701,000 after buying an additional 10,250 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Luminex by 26,778.2% in the third quarter. PNC Financial Services Group Inc. now owns 221,476 shares of the medical instruments supplier’s stock worth $6,712,000 after buying an additional 220,652 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Luminex by 0.8% in the third quarter. BlackRock Inc. now owns 6,644,013 shares of the medical instruments supplier’s stock worth $201,379,000 after buying an additional 50,973 shares in the last quarter. Hedge funds and other institutional investors own 86.59% of the company’s stock.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

Further Reading: Net Margin – Understanding the Different Kinds of Profit

Get a free copy of the Zacks research report on Luminex (LMNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.